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OBJECTIVES: PEGylated interferon beta-1a (PEG-IFN beta-1a) is being developed for
the treatment of relapsing-remitting multiple sclerosis (MS). PEGylated drugs are
commonly used in other therapeutic areas, including oncology and hepatitis, but
none are currently approved for MS. This study was conducted to gain a better
understanding of the published humanistic and patient quality of life benefits of
PEGylated drugs currently available for the treatment of other diseases.METHODS:
A comprehensive search of medical literature published between 1985 and 2010
was conducted using PubMed/MEDLINE and supplemental searches. Reviewed ref-
erenceswere prospective or retrospective studies reporting the tolerability, health-
related quality of life (HRQOL), convenience, compliance, and patient preferences
associated with PEGylated drugs. Only studies comparing PEGylated drugs to their
corresponding non-PEGylated counterparts in the same therapeutic area were in-
cluded in the analysis. RESULTS: Fifty-nine articles and 12 conference abstracts
were reviewed. Eleven PEGylated drugswere identified, 6 ofwhich had correspond-
ing non-PEGylated counterparts. All 6 of these PEGylated drugs were administered
less frequently than their non-PEGylated counterparts yet exhibited similar or
greater efficacy, along with greater patient convenience. PEGylated drugs were
generally tolerated as well as or better than their non-PEGylated counterparts. In
HRQOL studies, patientswho received PEGylated drugs reported betterHRQOL than
those receiving non-PEGylated drugs across a broad spectrum of domains, as well
as in global HRQOL scores. For studies measuring quality-adjusted life-years
(QALYs), PEGylated drugs were reported to produce more QALYs than their non-
PEGylated counterparts. While few studies have evaluated patient medication
compliance and patient preference/satisfaction, the published results of these
studies also favor PEGylated drugs.CONCLUSIONS: PEGylated drugs are reported to
be tolerated at least as well as their non-PEGylated counterparts and to be associ-
ated with higher HRQOL and greater patient preference/satisfaction, convenience,
and compliance. PEG-IFN beta-1a may offer similar benefits to patients with MS.
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IS EQ-5D A PROXY FOR SUBJECTIVE WELL-BEING? A STUDY OF THE
RELATIONSHIP BETWEEN HEALTH AND HAPPINESS IN PARKINSON’S DISEASE
PATIENTS
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OBJECTIVES: In light of the apparent disconnect between traditional measures of
societal well-being such as GDP and reported levels of happiness, governments
globally are turning their attention to alternative subjectivemeasures ofwell-being
(SWB) to aid policy decisions. In the context of health, there is therefore growing
interest in understanding how measures of health-related quality of life (HRQoL),
widely used in health technology appraisal, relates to SWB, and whether SWB
could provide a sound basis for resource allocation decisions in health and other
sectors in the future. This pilot study investigates the relationship betweenHRQoL,
as measured by EQ-5D, and SWB in Parkinson’s Disease (PD) and the extent to
which patients’ self-reported health can be used to predict their subjective
wellbeing.METHODS: A paper questionnaire including EQ-5D, four key SWB ques-
tions taken from the Office for National Statistics Integrated Household Survey in
England and other demographic details was distributed to people with PD in the
United Kingdom. Responses were used to estimate multiple regression models
explaining SWB using each of the EQ-5D Index (using UK weights), EQ-5D dimen-
sions and EQ-VAS andpatient socio-demographic characteristics.RESULTS:A total
of 276 questionnaires were distributed and 183 responses received. The EQ-5D
Index was generally a weak predictor of SWB in terms of life satisfaction, life being
worthwhile, and happiness (adjusted R2 from 0.13 - 0.26), but EQ-VAS performed
better (adjusted R2 from 0.28-0.40). The EQ-5D anxiety/depression dimensionwas a
reasonable predictor of anxiety (adjusted R20.34). CONCLUSIONS: The findings
imply that EQ-VAS and some dimensions of the EQ-5D, together with key demo-
graphic data such as household status, could potentially be used to predict SWBe.g.
via mapping. However further empirical research into the relationship between
SWB and EQ-5D longitudinally, and in different disease areas, is required to cor-
roborate these findings, and further standardisation of SWB measures is recom-
mended.
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OBJECTIVES: To assess and report utilization and patient perceptions of migraine
prophylaxis therapy in chronic migraine (CM) and episodic migraine (EM).
METHODS: A web-based survey evaluating the burden of migraine was adminis-
tered to 32,782 subjects from 6 countries. Responders (n16,663) were eligible for
themain questionnaire if they were 18 years of age, reported at least 1 headache
during the last 3 months, and reported symptoms meeting diagnostic criteria for
migraine. Eligible responders (n 1,183) were classified as CM or EM, based on
reported headache frequency (15 and 15 headache days per month, respec-
tively). For four medication classes (antidepressants, antiepileptics, beta blockers
and calcium channel blockers), subjects reporting current usage rated their overall
satisfaction, perception of headache improvement and experience with adverse
effects. RESULTS: Respondents (n1,165) were predominantly female (75.0%) with
a mean age of 43.6  12.2 years. 42.3% (n493) of subjects were classified as CM.
More CM subjects reported ever taking prophylaxis (CM vs. EM: 62.8% vs. 39.9%,
p0.001) and trying two ormore prophylactic therapies (CMvs. EM: 46.0% vs. 22.8%,
p0.001). Adjusting for age and gender, EM subjects were more likely to agree or
strongly agree that their headaches had improved and that theywere satisfiedwith
their prophylactic therapy (respectively: OR 2.1, p 0.001; OR 1.9, p 0.004). Adjusted
multivariate analyses showed similar results, but statistical significancewasmain-
tained for headache improvement only (respectively: OR 2.0, p 0.026; OR 1.2, p
0.584). CONCLUSIONS: These findings support previous reports that most mi-
graineurs, including many CM patients, have never tried prophylaxis. Though mi-
graine type (chronic vs. episodic) appears to influence patient perceptions of pro-
phylaxis, perceptions are multifactorial.
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FICTITIOUS PREFERENCES OR FELICITOUS RECODING? CONJOINT
RESPONDENTS WHO MAKE SENSE OF NONSENSICAL QUESTIONS
Yang JC, Johnson FR
RTI Health Solutions, Research Triangle Park, NC, USA
OBJECTIVES: Well-defined attributes are a cornerstone of choice-format conjoint
studies (discrete-choice experiments). However, little is known about how ill-de-
fined attributes affect the quality of stated-choice data. The objective of this study
was to evaluate choice responseswhen attribute levels in the choice options do not
align with a respondent’s personal current reference condition.METHODS: A total
of 193 US adults with self-reported epilepsy who reported taking antiepileptic
drugs (AEDs) to treat their seizures completed a web-enabled, choice-format con-
joint survey. Respondents responded to a series of choice questions to assess their
willingness to add another AED to control their seizures. Consistentwith endpoints
measured in a clinical trial, the efficacy attributewas defined as a 100%, 75%, 50% or
25% reduction in the number of seizures relative to the respondent’s current ref-
erence condition: each respondent’s own number of seizures over the last 3
months. Other treatment outcomes included short-term and long-term side ef-
fects, difficulty urinating, weight change, dosing frequency, and personal cost of
the add-on AED. RESULTS: Respondents’ current treatment generally achieved
good seizure control. Only one-third of the respondents reported having any sei-
zures and 20% reported having only 1 to 3 seizures. Nevertheless, aggregate pref-
erence estimates for the 100%, 75%, 50% or 25% seizure-reduction levels were cor-
rectly ordered, statistically different from each other (with one exception), and
were of sensible magnitudes relative to other treatment outcomes. Statistical tests
indicated that there was no difference in preferences between respondents with
4 seizures and those with 4 or more seizures. CONCLUSIONS: We have no infor-
mation about how patients with few or no seizures evaluated meaningless per-
centage reductions in their reference condition. Their reinterpretation of the attri-
bute levels, however, resulted in the same preference estimates as those for whom
the levels were consistent with their experience. Thus, our respondents may just
fix our mistakes.
PND36
STRUCTURED BENEFIT-RISK ASSESSMENT OF TRIPTAN TREATMENTS USING
PATIENT-PREFERENCE DATA
Gonzalez JM1, Hauber AB1, Levitan B2, Coplan P3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Johnson & Johnson PRD, Titusville, NJ,
USA, 3Purdue Pharma L.P., Stamford, CT, USA
OBJECTIVES: To demonstrate the use of trade-off preferences from a conjoint anal-
ysis in a structured framework for benefit-risk assessment ofmigraine treatments.
METHODS: Efficacy and safety endpoints from a hypothetical clinical study of
triptans in acute migraine were developed using the BRAT benefit-risk Framework
to identify and define endpoints as treatment benefits or harms. This decision
framework provides a foundation for selecting, organizing, understanding and
summarizing evidence relevant to benefit-risk decisions. To assess the relative
importance of these benefits and harms, we used a choice-format conjoint survey,
also known as discrete-choice experiment, to elicit migraineurs’ preferences for
clinical endpoints and to develop a set of importance weights for each endpoint.
These importance weights were then used to weigh mock clinical evidence and
demonstrate several means to assess the benefits and risks of triptans. We esti-
mated severalweightedmeasures of benefit-risk including incremental net clinical
benefit, the probability that benefit exceeds harm, and maximum acceptable risk.
RESULTS:A total of 201 self-reportedmigraineurs completed the conjoint-analysis
survey. The most important outcome evaluated by migraineurs was the chance of
dying from a myocardial infarction. The least important outcome was the chance
that a migraine would return 24 hours after taking medication. Preferences for
outcomes differed by gender. Weighted incremental net clinical benefit, the prob-
ability that benefit exceeds harm and maximum acceptable risk varied depending
on patient subgroup. CONCLUSIONS: Stakeholders routinely need to make judg-
ments about the relative value of benefits and risks associated with treatments.
Preference information is typically not explicitly used to aid in the evaluation of
clinical benefit and risk data. The use of preference information in the BRAT Frame-
work can help decision makers assess clinical evidence using a structured ap-
proach. The use of a variety of weighted benefit-risk measures provided several
perspectives by which decision makers can assess the decision.
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PREDICTORS OF POOR HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH
EPILEPSY: INSIGHT FROM THE PATIENTSLIKEME® EPILEPSY COMMUNITY
de la Loge C1, Dimova S1, Mueller K2, Durgin T3, Massagli MP4, Wicks P4
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OBJECTIVES: To identify predictors of poor health-related quality of life (HRQoL) in
members of the free online PatientsLikeMe Epilepsy Community. METHODS: The
PatientsLikeMe Epilepsy Community (launched January 2010) allows patients with
epilepsy to record, monitor and share their socio-demographic and disease char-
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acteristics, treatments, symptoms, seizure frequency and severity as well as com-
plete Patient Reported Outcomes (PRO) instruments (e.g. QOLIE-31/P, HADS). Uni-
variate and multivariate logistic regressions were performed to identify variables
associated with poor HRQoL (Quartile 1 of the QOLIE-31/P total score). RESULTS:
By May 2011, of the 2658 patients who had recorded a diagnosis of epilepsy and
multiple seizures, 1025 completed a PRO assessment and were included in this
analysis (mean age 37.5 years; 72.7% female; mean epilepsy duration from first
diagnosis 17.5 years). Median Q1-Q3 QOLIE-31/P total score was 50.5 (37.1-65.2),
with 256 patients being classifiedwith poor HRQoL. Multivariate logistic regression
indicated that poor HRQoL was more likely in patients reporting (Odds Ratio [95%
Confidence Interval]): 1)moderate/severe problems concentrating (3.19 [2.00-5.08]),
depression (2.61 [1.77-3.85]), memory problems (2.04 [1.29-3.24]), fatigue (1.75 [1.12-
2.71]), anxiety (1.49 [1.00-2.22]); 2) severe side effects (2.34 [1.39-3.92]); 3) at least one
tonic-clonic seizure during the 4 weeks before QOLIE-31/P completion (2.72 [1.65-
4.50]); 4) age 25-50 years (1.77 [1.01-3.11] vs. age 0-25 years); and 5) shorter epilepsy
duration (1 year 2.25 [1.23-4.13]; 1-10 years 1.70 [1.12-2.58]; both vs. 10 years).
Patients on polytherapy with newer antiepileptic drugs (AEDs) were less likely to
report poor HRQoL than patients on polytherapy with older AEDs (0.29 [0.11-0.74]).
CONCLUSIONS: These analyses indicate that moderate/severe problems concen-
trating, depression, the occurrence of generalized tonic-clonic seizures and of se-
vere side effects were the most predictive factors of poor HRQoL in the Patients-
LikeMe EpilepsyCommunity. These results suggest that a holistic approach beyond
seizure control should be considered when treating people with epilepsy.
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PATIENT-REPORTED BURDEN OF WALKING IMPAIRMENT IN MULTIPLE
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OBJECTIVES:Walking impairment (WI) is a disabling hallmark ofmultiple sclerosis
(MS). This patient-centric study aimed to assess the clinical, psychological, and
economic burden of WI. METHODS: This cross-sectional study compared MS pa-
tients with (test group: TG, PDDS0) and without (control group: CG,PDDS0). WI
as assessed by the Patient Determined Disease Steps (PDDS) questionnaire.
PDDS3 describes patients with mild WI while PDDS4 reflects patients using a
walking device. Using validated patient-reported outcomes instruments, falls, de-
pression (Center for Epidemiologic Studies Depression Scale) resource utilization,
and work productivity (Work Productivity and Activity Impairment Questionnaire)
were assessed. Chi-square and t-test provided statistical significance to p0.01.
RESULTS: 346 adult MS patients around 11 years post-diagnosis participated. WI
was significantly different across groups (TG:PDDS3.2vs.CG:PDDS0). In the TG,
patients with WI using a device reported more healthcare visits for WI than pa-
tients with mild WI (PDDS4:58%vs.PDDS3:13%). TG patients reported “falling
sometimes” significantly more than CG patients (PDDS3:62%; PDDS4:50% vs.
PDDS0:14%). Compared to CG patients, more PDDS3 TG patients reported visit-
ing the hospital/ER (11% vs. 5%) or doctor’s office (16%vs.5%) for falls. WI requiring
the use of a device (PDDS4) increased the reportedhealthcare visits (32%:hospital/
ER;27%:doctor’s visits). TG patients reported depression significantlymore than CG
patients and 40% of these TG patients explicitly linked depression to WI. Absen-
teeism (10%vs.5%) and impairmentwhile working (35%vs.18%)were reportedmore
often in TG compared to CG patients. CONCLUSIONS: In this sample, WI was as-
sociated with increased falls, health care utilization, depression and lesser work
productivity. WI requiring use of a device appears to increase these effects. WI
effects could not fully be isolated from cognitive impairment and other effects, and
confounding by indication could affect estimates. Multivariate model research is
needed to validate these results in a broader population and quantify associated
costs.
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WHAT IS THE INFLUENCE ON CLINICAL RESEARCH OF THE EMA GUIDELINE ON
MEDICINAL PRODUCTS FOR THE TREATMENT OF ALZHEIMER’S DISEASE?
Caron M, Acquadro C, Emery MP
MAPI Research Trust, Lyon, France
OBJECTIVES: In 2009, the EMA published a guideline onmedicinal products for the
treatment of Alzheimer’s disease. The guideline stipulates that symptoms im-
provement should be assessed in cognition (cognitive endpoint), activities of daily
living (functional endpoint) and overall clinical response (global endpoint). The two
primary endpoints should reflect the cognitive and functional domains. Global
assessment should be evaluated as a secondary endpoint. The objective of this
study is to review all products authorized by the EMA for the treatment of Alzhei-
mer’s before and after the publication of the guidance to see if the guidance had
any influence on clinical research or is only making existing practices official.
METHODS: The EMA website was searched with the keyword “Alzheimer” (EPAR
section, Keyword search). All EPARs and Scientific Discussions corresponding to
Alzheimer’s medicines were downloaded and reviewed. RESULTS: Ten products
were retrieved representing only two active substances: rivastigmine (8), and me-
mantine hydrochloride (2). Fourmedicineswere approved before the publication of
the guidance, and six afterwards (all generics of rivastigmine). The review of the
rivastigmine documents shows that the same studies were used for all products,
and that primary endpoints were cognitive and global; functional was secondary.
The review of the memantime documents shows that the same studies were used
for all products. For two studies, the EMA advised the sponsors that primary end-
points should be functional and global; cognitive was secondary. For two other
studies, global and cognitive measures were primary endpoints; functional was
secondary.CONCLUSIONS: Before 2009, symptoms improvement is assessed in the
three recommended domains. The primary and secondary endpoints, however,
were not always consistent with those advised by the guideline, and sometimes
contradicted them. The review cannot show any influence of the guidance on
clinical research since all products approved after its publication are generics of
rivastigmine.
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ASSESSMENT OF DEMENTIA RISK AMONG CAREGIVERS OF ALZHEIMER’S CARE
RECIPIENTS
Majethia U, Nayak R
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OBJECTIVES: Tomake an assessment of cognitive abilities of caregivers of individ-
uals with Alzheimer’s disease and to determine the risk of developing dementia in
this population. METHODS: A cross-sectional research design, utilizing a conve-
nience sample and one-on-one interviews, was adopted to address the study ob-
jectives. Family caregivers were recruited from New York City caregiver support
groups. Cognitive Abilities Screening Instrument (CASI), a pre-validated cognitive
scale, was used to assess the risk of dementia among the caregivers and a demo-
graphically similar sample of non-caregivers. CASI tests nine cognitive domains,
and a score of  74 on a scale between 1 and 100 indicates possible cognitive
impairment. The component scores of CASI were utilized to derive Mini Mental
State Examination (MMSE-CE) scores. Both MMSE-CE and individual component
scores of CASI were compared for the caregiver and non-caregiver groups.
RESULTS: The final data set consisted of 51 caregivers and 62 non-caregivers. Sig-
nificant differences were observed between the two with respect to CASI score (t
-2.311, p 0.001), MMSE-CE score (t -1.943, p 0.013) and individual domain
scores. Prevalence and number of medical conditions seemed to affect caregivers’
cognitive performance more than the non caregivers. Further, age and duration of
caregiving were revealed to be significant predictors of dementia risk in the care-
giver population based on both binary logistic (OR10.706, P 0.027,) andmultiple
linear regression (-0.306, P 0.028) models. CONCLUSIONS: This study provides
insights regarding the impact of caregiving on Alzheimer’s caregivers, specifically
with respect to their cognitive functioning. There is a greater likelihood of family
caregivers experiencing cognitive decline, significantly raising their risk of devel-
oping dementia sometime in the future. Health interventions should be designed
to make caregivers aware of the risks they face if they neglect their own health in
the process of caregiving.
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PARKINSON’S DISEASE QUESTIONNAIRE (PDQ-39) AS A PRIMARY ENDPOINT IN
A TRIAL COMPARING DEEP BRAIN STIMULATION WITH BEST MEDICAL
THERAPY VERSUS BEST MEDICAL THERAPY ALONE FOR ADVANCED
PARKINSON’S DISEASE (PD SURG TRIAL): A RANDOMISED, OPEN-LABEL TRIAL
Jenkinson C1, Williams A2, Ives N2, Rick C2, Daniels J2, Patel S2, Wheatley K2,
Churchman D3
1Health Services Research Unit, Department of Public Health, University of Oxford, Headington,
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OBJECTIVES: To assess whether combined surgery and best medical therapy re-
sulted in better outcomes than best medical therapy alone, in patients with ad-
vanced Parkinson’s disease (PD).METHODS: The PD SURG trial is an ongoing ran-
domised, open-label trial. At 13 neurosurgical centres in the UK, between
November 2000, and December 2006, patients with PD (that was not adequately
controlled bymedical therapy) were assigned to either, combined surgery and best
medical therapy, or to best medical therapy alone. The primary endpoint was the
quality of life PRO measure, the 39-item Parkinson’s disease questionnaire (PDQ-
39). Changes between baseline and 1 year were compared by use of t tests.
RESULTS: 366 patients were randomly assigned to receive immediate surgery and
bestmedical therapy (183) or bestmedical therapy alone (183). All patientswhohad
surgery had deep brain stimulation. At 1 year, the mean improvement in PDQ-39
summary index score compared with baseline was 5.0 points in the surgery group
and 0·3 points in the medical therapy group (difference –4·7, 95% CI –7·6 to –1·8;
p0.001); the difference in mean change in PDQ-39 score in the mobility domain
between the surgery group and the best medical therapy group was –8·9 (95% CI
–13·8 to –4·0; p0.0004), in the activities of daily living domain was –12·4 (–17·3 to
–7·5; p0.0001), and in the bodily discomfort domain was –7·5 (–12·6 to –2·4;
p0.004). Differences between groups in all other domains of the PDQ-39 were not
significant. Other serious adverse events will be reported. CONCLUSIONS: At one
year, surgery and best medical therapy improved patient self-reported quality of
life more than best medical therapy alone in patients with advanced Parkinson’s
disease. These differences are clinicallymeaningful, but surgery is not without risk
and targeting of patients most likely to benefit might be warranted.
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BURDEN OF DISEASE IN CAREGIVERS OF ALZHEIMER’S DISEASE IN BRAZIL:
RESULTS FROM 2011 NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)
Mould JF1, Fujii RK2, Paganini P2, Manfrin DF2
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OBJECTIVES: Alzheimer’s disease (AD) is the most common type of dementia for
which there is no cure. In a world where lifespan is increasing, dementia is becom-
ing more evident. In 2010, approximately 35.6 million people were living with de-
mentia and this number is likely to increase to 115.4 million in 2050. This study is
aimed to assess co-morbidity, quality of life (QOL), work/productivity loss, and
medical resource utilization in caregivers of AD in Brazil. METHODS: A total of
12,000 individuals’ (age 18) self-reported data were collected from 2011 National
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